OR WAIT null SECS
December 03, 2023
Collaboration is a key component to achieving long-term success with genetic medicines.
October 15, 2023
When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.
September 29, 2023
Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.
September 13, 2023
Seagen will be responsible for conjugating these degraders to antibodies to make DACs and advancing these DAC drug candidates through preclinical and clinical development and commercialization.
April 20, 2023
Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics
April 18, 2023
Jaeger notes that the program is focused on addressing specific scientific questions that will produce immediate impacts on how CDER and FDA make drug approval decisions.
December 13, 2022
The approval is based on results from the pivotal EFFISAYIL 1 Phase II clinical trial.
October 18, 2022
In this episode, Ana Ladino provides expert insight into novel excipients in the current and future drug development landscape.
October 15, 2022
How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.
October 04, 2022
An expert from Aptamer Group reveals the potential of Optimers (a type of aptamer) in the realm of drug delivery, including its targeting capabilities, scalability, and key differences between Optimers and antibody-drug conjugates.